Current guidelines provide a Class I recommendation for primary implantation of an implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy with a defibrillator (CRT-D) in patients with left ventricular ejection fraction (LVEF) ≤ 35%. However, the benefit of the ICD for primary prevention is not uniform due to differences in the risk of ventricular tachyarrhythmia (VTA) and non-arrhythmic mortality in patients with a low LVEF. Our team, led by Dr. Ilan Goldenberg and Dr. Arwa Younis developed a prediction model that integrates the risk of VTA with the risk of non-arrhythmic mortality in all 4531 patients with an ICD enrolled in the landmark MADIT trials (MADIT-II, MADIT-RISK, MADIT-CRT, and MADIT-RIT).
The MADIT-ICD Benefit Score, predicts the likelihood of ICD benefit through personalized assessment of the risk of VTA weighed against the risk of non-arrhythmic mortality.
We believe that our proposed MADIT-ICD Benefit Score can be used for shared decision-making in ICD candidates with a low LVEF.
Click here for MADIT ICD Benefit Score Calculator
Click here to read article